Results 21 to 30 of about 12,743 (165)

Prediction of drug resistance by Sanger sequencing of Mycobacterium tuberculosis complex strains isolated from multidrug resistant tuberculosis suspect patients in Ethiopia.

PLoS ONE, 2022
BackgroundEthiopia is one of the high multidrug-resistant tuberculosis (MDR-TB) burden countries. However, phenotypic drug susceptibility testing can take several weeks due to the slow growth of Mycobacterium tuberculosis complex (MTBC) strains.
Eyob Abera Mesfin, Matthias Merker, Dereje Beyene, Abreham Tesfaye, Yassir Adam Shuaib, Desalegn Addise, Belay Tessema, Stefan Niemann   +7 more
doaj   +1 more source

Characterization of pncA Mutations and Prediction of PZA Resistance in Mycobacterium tuberculosis Clinical Isolates From Chongqing, China

Frontiers in Microbiology, 2021
Pyrazinamide (PZA) is widely used to treat drug-sensitive or multidrug resistance tuberculosis. However, conventional PZA susceptibility tests of clinical isolates are rather difficult because of the requirement of acid pH.
Kun Li, Kun Li, Zhongping Yang, Jing Gu, Ming Luo, Jiaoyu Deng, Yaokai Chen   +6 more
doaj   +1 more source

Counting Pyrazinamide in Regimens for Multidrug-Resistant Tuberculosis [PDF]

Annals of the American Thoracic Society, 2015
Abstract Rationale For treatment of multidrug-resistant tuberculosis, World Health Organization (WHO) guidelines recommend four likely effective drugs plus pyrazinamide (PZA), irrespective of the likely effectiveness of PZA in an individual patient.
Molly F, Franke, Mercedes C, Becerra, Dylan B, Tierney, Michael L, Rich, Cesar, Bonilla, Jaime, Bayona, Megan M, McLaughlin, Carole D, Mitnick   +7 more
openaire   +2 more sources

The study of cross-resistance of MTB to certain anti-tuberculosis drugs among tuberculosis patients in Tomsk Region

Туберкулез и болезни лёгких, 2020
The objective of the study: to assess the prevalence of drug resistance of tuberculous mycobacteria (MTB) to pyrazinamide, linezolid, cross-resistance to fluoroquinolones, and cross-resistance to injectable anti-tuberculosis drugs among tuberculosis ...
P. N. Golubchikov, E. A. Kruk, S. P. Mishustin, V. E. Pavlova, D. Yu. Schegertsov, A. S. Аlliluev   +5 more
doaj   +1 more source

Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China

BMC Infectious Diseases, 2020
Background Pyrazinamide still may be a useful drug for treatment of rifampin-resistant (RR-TB) or multidrug-resistant tuberculosis (MDR-TB) in China while awaiting scale up of new drugs and regimens including bedaquiline and linezolid.
Hui Xia, Susan van den Hof, Frank Cobelens, Yang Zhou, Bing Zhao, Shengfen Wang, Yanlin Zhao   +6 more
doaj   +1 more source

Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan [PDF]

The International Journal of Tuberculosis and Lung Disease, 2018
The World Health Organization (WHO) recommends the inclusion of pyrazinamide (PZA) in treatment regimens for multidrug-resistant tuberculosis (MDR-TB) unless resistance has been confirmed.To investigate the association between PZA susceptibility and MDR-TB treatment outcome among patients treated with a PZA-containing regimen and whether the duration ...
Kuhlin, J, Smith, C, Khaemraev, A, Tigay, Z, Parpieva, N, Tillyashaykhov, M, Achar, J, Hajek, J, Greig, J, du Cros, P, Moore, D   +10 more
openaire   +2 more sources

Pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis isolates in Japan [PDF]

Clinical Microbiology and Infection, 2010
Thirty-six multidrug-resistant (MDR) Mycobacterium tuberculosis isolates collected in Japan were examined for pyrazinamide susceptibility and pyrazinamidase activity, and analysed by pncA sequencing and a hybridization-based line probe assay (LiPA), which was used to detect pncA mutations for the rapid identification of pyrazinamide-resistant isolates.
Ando, H., Mitarai, S., Kondo, Y., Suetake, T., Sekiguchi, J.-I., Kato, S., Mori, T., Kirikae, T.   +7 more
openaire   +2 more sources

Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide [PDF]

Antimicrobial Agents and Chemotherapy, 1995
The mechanism of action of pyrazinamide (PZA) is not known. One hypothesis is that PZA functions as a prodrug of pyrazinoic acid. Susceptibility to PZA correlates with amidase activity of the Mycobacterium tuberculosis isolate in question. PZA-resistant isolates retain susceptibility in vitro to pyrazinoic acid and n-propyl pyrazinoate.
R J, Speirs, J T, Welch, M H, Cynamon
openaire   +2 more sources

Pyrazinamide Susceptibility Is Driven by Activation of the SigE-Dependent Cell Envelope Stress Response in Mycobacterium tuberculosis

mBio, 2022
Pyrazinamide (PZA) plays a crucial role in first-line tuberculosis drug therapy. Unlike other antimicrobial agents, PZA is active against Mycobacterium tuberculosis only at low pH. The basis for this conditional drug susceptibility remains undefined.
Joshua M. Thiede, Nicholas A. Dillon, Michael D. Howe, Ranee Aflakpui, Samuel J. Modlin, Sven E. Hoffner, Faramarz Valafar, Yusuke Minato, Anthony D. Baughn   +8 more
doaj   +1 more source

Impact of genotypic and phenotypic resistance to second-line anti-tuberculosis drugs on treatment outcomes in multidrug-resistant tuberculosis in China

International Journal of Mycobacteriology, 2016
Background: Despite the strong association between drug resistance and genetic mutations, the value of molecular diagnosis of drug resistance to guide the treatment of multidrug-resistant tuberculosis (MDR-TB) remains unclear.
Yi Hu, Xubin Zheng, Zhu Ning, Qun Li, Zhengdong Zhang, Sven Hoffner   +5 more
doaj   +1 more source